FY2025 Earnings Forecast for Neogen Issued By Zacks Research

Neogen Co. (NASDAQ:NEOG) – Analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Neogen in a report released on Wednesday, February 12th. Zacks Research analyst R. Department now forecasts that the company will earn $0.38 per share for the year, down from their prior forecast of $0.39. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.57 EPS.

Neogen (NASDAQ:NEOG) last announced its quarterly earnings data on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. During the same quarter in the prior year, the company posted $0.11 earnings per share. Neogen’s quarterly revenue was up .7% on a year-over-year basis.

Several other research firms have also weighed in on NEOG. Guggenheim began coverage on Neogen in a report on Thursday, December 19th. They issued a “buy” rating and a $15.00 target price on the stock. Piper Sandler reissued a “neutral” rating and issued a $13.00 target price (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st.

Neogen Stock Down 0.9 %

Neogen stock opened at $9.83 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.46 and a current ratio of 3.77. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -4.49 and a beta of 1.23. Neogen has a fifty-two week low of $9.70 and a fifty-two week high of $18.58. The stock’s fifty day moving average is $11.78 and its two-hundred day moving average is $14.21.

Insider Buying and Selling at Neogen

In related news, CFO David H. Naemura acquired 14,800 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were acquired at an average price of $11.11 per share, with a total value of $164,428.00. Following the completion of the purchase, the chief financial officer now directly owns 61,434 shares in the company, valued at approximately $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Edward Adent acquired 23,035 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were bought at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the purchase, the chief executive officer now owns 269,164 shares of the company’s stock, valued at approximately $2,968,878.92. The trade was a 9.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is owned by corporate insiders.

Institutional Trading of Neogen

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Neogen by 9.8% during the fourth quarter. Vanguard Group Inc. now owns 21,637,251 shares of the company’s stock valued at $262,676,000 after acquiring an additional 1,928,491 shares during the last quarter. Norges Bank purchased a new position in Neogen during the fourth quarter worth about $212,171,000. William Blair Investment Management LLC lifted its position in Neogen by 8.1% during the fourth quarter. William Blair Investment Management LLC now owns 14,346,759 shares of the company’s stock worth $174,170,000 after buying an additional 1,074,825 shares during the period. Conestoga Capital Advisors LLC lifted its position in Neogen by 24.5% during the third quarter. Conestoga Capital Advisors LLC now owns 8,706,224 shares of the company’s stock worth $146,352,000 after buying an additional 1,711,238 shares during the period. Finally, State Street Corp lifted its position in Neogen by 3.1% during the third quarter. State Street Corp now owns 7,932,192 shares of the company’s stock worth $133,340,000 after buying an additional 236,762 shares during the period. Institutional investors and hedge funds own 96.73% of the company’s stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.